US FDA policy change: not all new medication guides need to be part of REMS
This article was originally published in SRA
Executive Summary
In a major policy shift, the US Food and Drug Administration has issued draft guidance clarifying that not all newly required medication guides for prescription drugs and biologics need to be included in a risk evaluation and mitigation strategy (REMS) programme1,2.